دورية أكاديمية
أعرض في EDS

New Strategy for Promoting Vascularization in Tumor Spheroids in a Microfluidic Assay.

التفاصيل البيبلوغرافية
العنوان: New Strategy for Promoting Vascularization in Tumor Spheroids in a Microfluidic Assay.
المؤلفون: Wan Z; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Floryan MA; Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA., Coughlin MF; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA., Zhang S; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA., Zhong AX; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA., Shelton SE; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Wang X; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA., Xu C; School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong, 510515, China., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Kamm RD; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.; Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
المصدر: Advanced healthcare materials [Adv Healthc Mater] 2023 Jun; Vol. 12 (14), pp. e2201784. Date of Electronic Publication: 2022 Nov 15.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 101581613 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2192-2659 (Electronic) Linking ISSN: 21922640 NLM ISO Abbreviation: Adv Healthc Mater Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Weinheim : Wiley-VCH, 2012-
مواضيع طبية MeSH: Microfluidics* , Spheroids, Cellular*, Humans ; Neovascularization, Pathologic ; Cell Line, Tumor
مستخلص: Previous studies have developed vascularized tumor spheroid models to demonstrate the impact of intravascular flow on tumor progression and treatment. However, these models have not been widely adopted so the vascularization of tumor spheroids in vitro is generally lower than vascularized tumor tissues in vivo. To improve the tumor vascularization level, a new strategy is introduced to form tumor spheroids by adding fibroblasts (FBs) sequentially to a pre-formed tumor spheroid and demonstrate this method with tumor cell lines from kidney, lung, and ovary cancer. Tumor spheroids made with the new strategy have higher FB densities on the periphery of the tumor spheroid, which tend to enhance vascularization. The vessels close to the tumor spheroid made with this new strategy are more perfusable than the ones made with other methods. Finally, chimeric antigen receptor (CAR) T cells are perfused under continuous flow into vascularized tumor spheroids to demonstrate immunotherapy evaluation using vascularized tumor-on-a-chip model. This new strategy for establishing tumor spheroids leads to increased vascularization in vitro, allowing for the examination of immune, endothelial, stromal, and tumor cell responses under static or flow conditions.
(© 2022 The Authors. Advanced Healthcare Materials published by Wiley-VCH GmbH.)
References: Sci Rep. 2016 Aug 23;6:31589. (PMID: 27549930)
Biomicrofluidics. 2021 Nov 09;15(6):061503. (PMID: 34804315)
Adv Healthc Mater. 2019 Mar;8(5):e1900001. (PMID: 30734529)
Front Immunol. 2019 Feb 05;10:128. (PMID: 30804938)
Adv Biol (Weinh). 2021 Jul;5(7):e2100090. (PMID: 33857356)
Mol Cancer Ther. 2008 Sep;7(9):2746-57. (PMID: 18790755)
Front Bioeng Biotechnol. 2022 Feb 08;10:764237. (PMID: 35211462)
Mol Cancer Ther. 2012 Jul;11(7):1576-86. (PMID: 22700681)
Sci Immunol. 2021 Mar 26;6(57):. (PMID: 33771887)
Nat Rev Cancer. 2019 Feb;19(2):65-81. (PMID: 30647431)
Small Methods. 2022 Jun;6(6):e2200143. (PMID: 35373502)
Tissue Eng Part C Methods. 2013 Sep;19(9):730-7. (PMID: 23320912)
Integr Biol (Camb). 2009 Dec;1(11-12):649-54. (PMID: 20027373)
ACS Biomater Sci Eng. 2022 Mar 14;8(3):1215-1225. (PMID: 35167260)
Blood Cancer J. 2021 Apr 6;11(4):69. (PMID: 33824268)
Cell Rep. 2017 Oct 10;21(2):508-516. (PMID: 29020635)
Cancer Immunol Res. 2019 Feb;7(2):183-192. (PMID: 30651288)
Biomaterials. 2020 Jun;243:119921. (PMID: 32172030)
Dev Biol. 2005 Feb 1;278(1):255-63. (PMID: 15649477)
ACS Nano. 2017 Jul 25;11(7):6691-6702. (PMID: 28614653)
N Engl J Med. 2018 Jul 5;379(1):64-73. (PMID: 29972754)
Microsyst Nanoeng. 2021 Jun 21;7:50. (PMID: 34567763)
PLoS One. 2020 Oct 28;15(10):e0240552. (PMID: 33112918)
Mol Biol Cell. 2011 Oct;22(20):3791-800. (PMID: 21865599)
Cell Death Dis. 2019 Jun 17;10(7):476. (PMID: 31209210)
Trends Pharmacol Sci. 2019 Sep;40(9):613-623. (PMID: 31331639)
Signal Transduct Target Ther. 2020 Jul 29;5(1):134. (PMID: 32728035)
Lab Chip. 2021 Mar 21;21(6):1150-1163. (PMID: 33538719)
J Invest Dermatol. 1986 Mar;86(3):279-85. (PMID: 3745952)
Cell Mol Bioeng. 2014 Mar 1;7(1):15-25. (PMID: 24660039)
Nat Cell Biol. 2017 Mar;19(3):224-237. (PMID: 28218910)
Sci Rep. 2017 Aug 14;7(1):8083. (PMID: 28808270)
Adv Funct Mater. 2012 Nov 7;22(21):4511-4518. (PMID: 23536744)
Biol Blood Marrow Transplant. 2019 Apr;25(4):e123-e127. (PMID: 30586620)
Nat Rev Mol Cell Biol. 2005 Aug;6(8):622-34. (PMID: 16025097)
Cell. 2020 Jan 9;180(1):188-204.e22. (PMID: 31883794)
ACS Nano. 2019 Jul 23;13(7):7627-7643. (PMID: 31194909)
Cancer Discov. 2016 Feb;6(2):133-46. (PMID: 26503962)
Lab Chip. 2021 Jun 1;21(11):2142-2152. (PMID: 33913456)
Biomaterials. 2021 Sep;276:121032. (PMID: 34303155)
Adv Funct Mater. 2022 Oct 21;32(43):. (PMID: 36569597)
Front Immunol. 2022 Jul 05;13:901277. (PMID: 35865534)
Science. 2018 Mar 23;359(6382):1361-1365. (PMID: 29567707)
Adv Funct Mater. 2020 Nov 25;30(48):. (PMID: 33692661)
Mater Today (Kidlington). 2022 Jun;56:79-95. (PMID: 36188120)
Biotechnol Bioeng. 2018 Nov;115(11):2793-2806. (PMID: 29940072)
Adv Sci (Weinh). 2019 Feb 10;6(8):1801531. (PMID: 31016107)
Annu Rev Biomed Eng. 2021 Jul 13;23:141-167. (PMID: 33756087)
Cell Discov. 2021 Sep 14;7(1):84. (PMID: 34518515)
Circ Res. 2005 Nov 25;97(11):1093-107. (PMID: 16306453)
Front Immunol. 2020 Sep 04;11:2090. (PMID: 33013881)
Integr Biol (Camb). 2020 Sep 30;12(9):221-232. (PMID: 32930334)
Breast Cancer Res. 2003;5(6):R217-22. (PMID: 14580257)
Nat Rev Cancer. 2020 Mar;20(3):174-186. (PMID: 31980749)
Mol Cancer. 2006 Nov 03;5:56. (PMID: 17083723)
Curr Opin Hematol. 2008 May;15(3):215-20. (PMID: 18391788)
Clin Cancer Res. 2014 Feb 15;20(4):938-50. (PMID: 24284055)
Cell Mol Life Sci. 2008 Nov;65(23):3756-88. (PMID: 18726070)
Blood Cancer Discov. 2022 Mar 01;3(2):136-153. (PMID: 35015685)
Nat Rev Mol Cell Biol. 2010 Jul;11(7):502-14. (PMID: 20571587)
J Biomech. 2021 Apr 15;119:110330. (PMID: 33631662)
Adv Sci (Weinh). 2020 Sep 21;7(21):2002002. (PMID: 33173735)
IEEE Open J Eng Med Biol. 2022 May 27;3:86-95. (PMID: 35813488)
Exp Hematol Oncol. 2020 Jun 08;9:11. (PMID: 32523801)
Biomaterials. 2020 Jan;229:119547. (PMID: 31710953)
Front Immunol. 2020 Jun 17;11:1109. (PMID: 32625204)
BMJ. 1999 Aug 7;319(7206):332-4. (PMID: 10435939)
Blood. 2019 Feb 14;133(7):697-709. (PMID: 30463995)
Adv Drug Deliv Rev. 2021 Aug;175:113798. (PMID: 34015419)
Adv Funct Mater. 2020 Nov 25;30(48):. (PMID: 33692660)
Cell Commun Signal. 2020 Apr 7;18(1):59. (PMID: 32264958)
Nat Cell Biol. 2008 Apr;10(4):429-36. (PMID: 18364700)
Exp Cell Res. 2008 Nov 15;314(19):3444-52. (PMID: 18824166)
Cancer Res. 2010 Feb 1;70(3):1063-71. (PMID: 20103651)
Nat Rev Drug Discov. 2021 Jul;20(7):531-550. (PMID: 33972771)
Sci Rep. 2017 Jun 7;7(1):2963. (PMID: 28592821)
Lab Chip. 2019 Jan 29;19(3):369-386. (PMID: 30644496)
Lab Chip. 2013 Apr 21;13(8):1489-500. (PMID: 23440068)
Sci Adv. 2021 Feb 17;7(8):. (PMID: 33597234)
Lab Chip. 2016 Jan 21;16(2):282-90. (PMID: 26616908)
Lab Chip. 2019 Sep 7;19(17):2822-2833. (PMID: 31360969)
NPJ Regen Med. 2020 Jan 6;5:1. (PMID: 31934351)
J Biol Chem. 2020 Feb 21;295(8):2495-2505. (PMID: 31937589)
Lab Chip. 2021 Apr 7;21(7):1333-1351. (PMID: 33605955)
Proc Natl Acad Sci U S A. 2022 Jun 7;119(23):e2118697119. (PMID: 35648828)
معلومات مُعتمدة: K00 CA212227 United States CA NCI NIH HHS; P30 CA014051 United States CA NCI NIH HHS; U01 CA214381 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: chimeric antigen receptor-T cells; continuous flow; fibroblasts; tumor-on-a-chip; vascularization
تواريخ الأحداث: Date Created: 20221105 Date Completed: 20230605 Latest Revision: 20230919
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10156888
DOI: 10.1002/adhm.202201784
PMID: 36333913
قاعدة البيانات: MEDLINE
الوصف
تدمد:2192-2659
DOI:10.1002/adhm.202201784